Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000730539 | SCV000858284 | pathogenic | not provided | 2017-11-20 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001784362 | SCV002020475 | pathogenic | Dubin-Johnson syndrome | 2019-07-29 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000730539 | SCV004305585 | likely pathogenic | not provided | 2024-01-06 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 26 of the ABCC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ABCC2 are known to be pathogenic (PMID: 9185779, 16549534, 16952291). This variant is present in population databases (rs34937870, gnomAD 0.01%). Disruption of this splice site has been observed in individual(s) with Dubin-Johnson syndrome (PMID: 31544333). ClinVar contains an entry for this variant (Variation ID: 595090). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |